Related Experiment Video
Updated: Feb 6, 2026
09:27
Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues
Published on: February 17, 2017
10.8K
When and How to Use Somatostatin Analogues
1Department of Internal Medicine, Sector of Endocrinology, ENETS Center of Excellence for Neuroendocrine Tumors, Erasmus MC, Dr. Molewaterplein 40, Rotterdam 3015 GD, The Netherlands.
Endocrinology and Metabolism Clinics of North America
|August 13, 2018
Summary
Long-acting depot somatostatin analogues are the primary treatment for controlling hormonal imbalances and tumors in neuroendocrine tumors of the gastrointestinal tract and pancreas. These treatments target specific somatostatin receptors on tumor cells.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Neuroendocrine tumors (NETs) in the gastrointestinal tract and pancreas often cause hormonal excess.
- Current treatments focus on managing hormonal symptoms and tumor growth.
- Somatostatin receptor expression is a key characteristic of these tumors.
Purpose of the Study:
- To highlight the role of long-acting depot somatostatin analogues in managing NETs.
- To emphasize their efficacy in both hormone-producing and non-hormone-producing NETs.
- To explain the mechanism of action involving somatostatin receptor subtypes.
Main Methods:
- Review of current clinical guidelines and treatment protocols for NETs.
- Analysis of the pharmacological properties of somatostatin analogues.
- Examination of somatostatin receptor expression patterns in gastrointestinal and pancreatic NETs.
Main Results:
- Long-acting depot somatostatin analogues are established as first-line therapy for NETs.
- These formulations effectively control hormonal excess.
- They also contribute to tumor control in both hormone-producing and non-hormone-producing NETs.
Conclusions:
- Somatostatin analogues are crucial for managing gastrointestinal and pancreatic NETs.
- Their efficacy relies on targeted interaction with specific somatostatin receptor subtypes.
- These agents represent a cornerstone in the first-line treatment strategy for NETs.
